American Society of Hirudotherapy

Resolution of thrombocytopenia through sodium bicarbonate intervention as an alternative diluent for heparin in an extracorporeal membrane oxygenation patient: a case report

Research article published in Journal of medical case reports (2026)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsAlFaifi et al. · Journal of medical case reports, 2026

Abstract

BACKGROUND: Thrombocytopenia is a common and multifaceted complication in patients receiving heparin therapy during extracorporeal membrane oxygenation (ECMO). Its development may result from several mechanisms, such as platelet consumption, hemodilution, shear stress, circuit activation, and heparin-induced thrombocytopenia. Managing thrombocytopenia in this context can be challenging. Therefore, we present a patient who developed thrombocytopenia while receiving a heparin infusion, which resolved after changing the infusion diluent. CASE PRESENTATION: We presented a case of a 64-year-old Pakistani male with multiple cardiac comorbidities who was admitted in a critical condition following cardiac arrest, requiring immediate resuscitation and veno-arterial ECMO initiation for circulatory support. During the ICU course, he developed thrombocytopenia while on heparin infusion diluted in D5W. Despite ruling out heparin-induced thrombocytopenia, his platelet counts continued to decline. As an alternative approach, the heparin diluent was switched to sodium bicarbonate, leading to recovery in platelet levels without the need for transfusion. CONCLUSIONS: This case highlights a possible association between using sodium bicarbonate as a diluent for heparin infusion and platelet recovery. While this finding warrants further investigation, additional studies are necessary to determine its broader clinical implications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This single case report describes a 64-year-old ECMO patient on heparin who developed worsening thrombocytopenia despite ruling out heparin-induced thrombocytopenia (HIT); per the abstract, switching the heparin diluent from D5W to sodium bicarbonate was followed by platelet recovery without transfusion. For the hirudotherapy evidence picture this sits in the broader anticoagulation-safety context rather than touching leech therapy directly: it illustrates the well-known difficulty of managing heparin-related platelet problems, the clinical backdrop against which direct thrombin inhibitors derived from the medicinal-leech secretome (hirudin and analogues) are of interest because they act independently of platelet factor 4. Caveat: this is an uncontrolled single-patient observation, the authors themselves call the diluent-platelet link only a possible association needing further study, and it involves no leech-derived agent.

Citation

Resolution of thrombocytopenia through sodium bicarbonate intervention as an alternative diluent for heparin in an extracorporeal membrane oxygenation patient: a case report.

AlFaifi et al. · Journal of medical case reports, 2026

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.